- Home
- PLXS vs MIRM Comparison
PLXS vs MIRM Comparison
Compare PLXS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- MIRM
- Stock Information
- Founded
- PLXS 1979
- MIRM 2018
- Country
- PLXS United States
- MIRM United States
- Employees
- PLXS N/A
- MIRM N/A
- Industry
- PLXS Electrical Products
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- MIRM Health Care
- Exchange
- PLXS Nasdaq
- MIRM Nasdaq
- Market Cap
- PLXS 3.7B
- MIRM 3.3B
- IPO Year
- PLXS 1986
- MIRM 2019
- Fundamental
- Price
- PLXS $142.76
- MIRM $75.32
- Analyst Decision
- PLXS Strong Buy
- MIRM Strong Buy
- Analyst Count
- PLXS 5
- MIRM 10
- Target Price
- PLXS $154.50
- MIRM $74.20
- AVG Volume (30 Days)
- PLXS 142.0K
- MIRM 690.6K
- Earning Date
- PLXS 10-22-2025
- MIRM 11-11-2025
- Dividend Yield
- PLXS N/A
- MIRM N/A
- EPS Growth
- PLXS 47.80
- MIRM N/A
- EPS
- PLXS 5.87
- MIRM N/A
- Revenue
- PLXS $4,025,169,000.00
- MIRM $429,161,000.00
- Revenue This Year
- PLXS $3.54
- MIRM $53.08
- Revenue Next Year
- PLXS $8.27
- MIRM $20.45
- P/E Ratio
- PLXS $24.32
- MIRM N/A
- Revenue Growth
- PLXS 2.31
- MIRM 62.33
- 52 Week Low
- PLXS $103.43
- MIRM $36.86
- 52 Week High
- PLXS $172.89
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- PLXS 63.28
- MIRM 63.94
- Support Level
- PLXS $135.46
- MIRM $73.35
- Resistance Level
- PLXS $141.24
- MIRM $74.99
- Average True Range (ATR)
- PLXS 2.92
- MIRM 2.47
- MACD
- PLXS 0.18
- MIRM -0.86
- Stochastic Oscillator
- PLXS 93.05
- MIRM 55.42
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.